股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 首都創投有限公司 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02324 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 800,000,000 | HKD | | 0.25 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 800,000,000 | HKD | | 0.25 | HKD | | 200,000,000 | 本月底法定/註冊股本總額： ...

Core Viewpoint - Capital Venture (02324) reported an annual performance for the year ending September 30, 2025, showing a positive trend in investment returns and net profit, indicating a recovery from previous losses [1] Financial Performance - Investment income reached approximately HKD 20.66 million, representing a year-on-year increase of 4.08% [1] - Net profit was approximately HKD 131 million, marking a turnaround from previous losses [1] - Earnings per share stood at HKD 0.29 [1]

Core Viewpoint - Capital Venture (02324) reported an annual performance for the year ending September 30, 2025, showing a significant recovery with a net profit of approximately HKD 131 million, marking a turnaround from previous losses [1] Financial Performance - Investment income reached approximately HKD 20.66 million, reflecting a year-on-year growth of 4.08% [1] - Earnings per share stood at HKD 0.29, indicating a positive shift in profitability [1]

Financial Performance - For the fiscal year ending September 30, 2025, the company reported a net profit of HKD 131,088,977, a significant recovery from a loss of HKD 19,915,626 in the previous year[3] - The company reported a pre-tax profit of HKD 131,088,977 for the year ending September 30, 2025, compared to a pre-tax loss of HKD 20,326,277 in the previous year[16] - Total comprehensive income for the year 2025 was HKD 131,088,977, a significant recovery from a loss of HKD 19,915,626 in 2024[25] - Net profit attributable to equity holders was approximately HKD 131,100,000 for the current year, a significant recovery from a net loss of HKD 19,900,000 in the previous year[33] Investment Income - The company's investment income increased to HKD 20,660,012, up from HKD 19,849,416, reflecting a growth of approximately 4.1% year-over-year[3] - The net investment income (loss) for the year ending September 30, 2025, was HKD 125,276,732, compared to a loss of HKD 22,181,450 for the previous year[14] - The group's listed investments generated a profit of HKD 125,300,000, reversing a loss of HKD 22,100,000 from the previous year[33] - The group recorded total investment income of approximately HKD 125,300,000 from listed securities for the year ended September 30, 2025[60] - The group generated bond interest income of HKD 20,600,000 during the same period[60] Assets and Liabilities - The total assets of the company rose to HKD 417,715,571, compared to HKD 209,094,102 in the previous year, indicating a growth of about 99.9%[4] - Total assets as of September 30, 2025, were HKD 474,939,165, up from HKD 352,974,554 in the previous year, indicating a growth of approximately 34.5%[18] - Total liabilities decreased to HKD 36,344,050 as of September 30, 2025, from HKD 45,468,416 in 2024, representing a reduction of about 20.2%[18] - The company's equity attributable to shareholders increased to HKD 438,595,115 from HKD 307,506,138, reflecting a growth of approximately 42.6%[4] Cash and Financing - The cash and cash equivalents increased to HKD 38,258,394 from HKD 25,178,400, marking a growth of approximately 51.8%[4] - The company reported a decrease in financing costs to HKD 3,582,063 from HKD 6,396,834, a reduction of about 44.5%[3] - The total employee costs, including directors' remuneration, decreased to HKD 3,553,561 in 2025 from HKD 3,796,543 in 2024, a decline of about 6.4%[23] - The group has pledged listed stocks valued at approximately HKD 82,400,000 as collateral for margin financing[56] Corporate Governance - The company has adhered to the corporate governance code as per the listing rules, with the exception of the separation of roles between the Chairman and CEO, which is managed collectively by the executive directors[64] - The audit committee, composed of three independent non-executive directors, held three meetings this year to review financial reporting, risk management, and internal control systems[67] - The company has a robust corporate governance structure to effectively supervise management, ensuring adaptability to changing environments[64] - The board consists of both executive and independent non-executive directors, ensuring a diverse governance structure[70] Accounting Standards - The company has adopted new and revised Hong Kong Financial Reporting Standards, which did not have a significant impact on the financial position and performance for the year[7] - The company expects that the adoption of new accounting standards will not have a significant impact on its financial performance or position[12] - The new Hong Kong Financial Reporting Standard 18 will come into effect for annual periods beginning on or after January 1, 2027, allowing for early adoption[12] Market Position and Strategy - The company aims to strengthen its market position and expand capacity in response to the growing demand in the umbrella market[46] - Japan Symbiosis Group plans to diversify its business by investing in modern logistics and data centers to adapt to the rapid transformation driven by e-commerce and digitalization[48] Other Financial Metrics - The current ratio improved from 4.6 to 11.5, indicating a strong liquidity position[38] - The debt-to-equity ratio decreased to 8.0% from 14.0% in the previous year, reflecting a low level of leverage[39] - The company did not declare any dividends for the year ending September 30, 2025, consistent with the previous year[24] - The company has recognized expected credit losses of approximately HKD 3,000,000 for bond investments and HKD 400,000 for receivables from the sale of investments during the year[52]

Market Overview - The Hong Kong stock market experienced fluctuations on December 22, with the Hang Seng Index rising by 0.43% to close at 25,801.77 points, the Hang Seng Tech Index increasing by 0.87% to 5,526.83 points, and the National Enterprises Index up by 0.43% to 8,939.68 points [1] - Major technology stocks showed mixed performance, with Alibaba up by 0.76%, Tencent Holdings up by 0.08%, and JD Group up by 0.9%, while Xiaomi fell by 1.83% and NetEase by 0.09% [1] - The optical communication sector was strong, with Huiju Technology rising by 13% and Changfei Optical Fiber Cable up by 11% [1] - Duty-free concept leader China Duty Free Group surged over 15%, while the new consumption sector saw significant gains, with Mixue Group up over 10% and Pop Mart up over 4% [1] - Chip stocks also rose, with SMIC increasing by nearly 6% and Hua Hong Semiconductor up over 5% [1] - Gold stocks generally rose, with China National Gold up over 7% and Shandong Gold up over 5% [1] - Four new stocks were listed, including Impression Dahongpao and Huacheng Biotechnology, all of which experienced a decline in their initial trading [1] Company News - SF Holding reported a total revenue of 27.173 billion yuan for November, a year-on-year increase of 7.85%, with express logistics revenue growing by 9.88% and business volume increasing by 20.13% [2] - Capital Venture expects to achieve an unaudited net profit of approximately 115 million to 140 million HKD for the fiscal year ending September 30, 2025, marking a turnaround from losses, primarily due to improved performance in listed equity investments [2] - Tianqi Lithium announced the completion of the third phase of its chemical-grade lithium concentrate expansion project, which has officially commenced trial production [3] - Qingdao Port plans to purchase two assets from the cruise port development for the Qingdao Shipping Financial Center [4] - CanSino Biologics has initiated Phase I clinical trials for its DTCP–HIb–MCV4 combined vaccine, completing the enrollment of the first subject [5] - Junshi Biosciences received FDA approval for the Phase I clinical trial application of its biosimilar HLX18 for the treatment of various solid tumors [5] - China National Nuclear Corporation's subsidiary, CNNC Haidewei, received clinical approval for its BNCT boron drug [6] - Hisense Home Appliances subscribed to a financial product from Jingu Trust worth 1.892 billion yuan [7] - Evergrande Property's liquidator has received several updated non-binding offers from selected bidders, which are currently under consideration [7] - Ruian Construction completed the sale of Ruian Property Management Services [8] - Tianjin Port Development's subsidiary plans to purchase ten gantry cranes for 185 million yuan [9] Institutional Insights - CITIC Securities noted that after a strong rally in September, the Hong Kong market has experienced fluctuations since October due to varying overseas macro expectations, with quality assets becoming more attractive [10] - Huatai Securities indicated that the market is still in a left-side layout phase, with uncertainties surrounding the "Santa rally" and potential supply-demand pressures at year-end [10] - China Galaxy suggested focusing on the technology sector as a long-term investment theme, which has seen valuation corrections and may rebound due to multiple favorable factors [10] - The consumption sector is expected to receive significant policy support, with current valuations at relatively low levels, indicating potential for long-term growth [10]

Company News - SF Holding (06936.HK) reported a total revenue of 27.173 billion yuan for its express logistics, supply chain, and international business in November, representing a year-on-year growth of 7.85%. The express logistics business revenue grew by 9.88%, with a business volume increase of 20.13% [2] - Capital Investment (02324.HK) expects to achieve an unaudited consolidated net profit of approximately 115 million to 140 million HKD for the fiscal year ending September 30, 2025, marking a turnaround from losses, primarily due to the performance of listed equity investments [2] - Tianqi Lithium (09696.HK) has completed the construction of the third phase of its chemical-grade lithium concentrate expansion project and has officially commenced trial production [2] - Qingdao Port (06198.HK) plans to purchase two assets from the Qingdao Shipping Financial Center for the development of a cruise port [2] - CanSino Biologics (06185.HK) has initiated Phase I clinical trials for its DTCP–HIb–MCV4 combined vaccine and completed the enrollment of the first subject [2] - Fuhong Hanlin (02696.HK) received approval from the U.S. Food and Drug Administration for its application for the Phase I clinical trial of HLX18, a biosimilar to Nivolumab for the treatment of various solid tumors [2] - China National Nuclear Corporation (01763.HK) announced that its subsidiary, CNNC Haidewei, has received clinical approval for its BNCT boron drug [2] - Hisense Home Appliances (00921.HK) subscribed to a financial product from Jingu Trust for 1.892 billion yuan [2] Acquisition and Disposal - Evergrande Property (06666.HK) has received several updated non-binding offers from selected bidders, which the liquidators are currently considering [3] - Ruian Construction (00983.HK) has completed the sale of Ruian Property Management Services Co., Ltd. [4] - Tianjin Port Development (03382.HK) plans to purchase ten gantry cranes for 185 million yuan [5] Buyback Activities - Tencent Holdings (00700.HK) repurchased 1.036 million shares at a cost of 636 million HKD, with buyback prices ranging from 607 to 617 HKD [5] - Xiaomi Group-W (01810.HK) repurchased 3.75 million shares for 152 million HKD, with buyback prices between 40.42 and 40.56 HKD [6] - COSCO Shipping Holdings (01919.HK) repurchased 3.9655 million shares for 53.6689 million HKD, with buyback prices ranging from 13.47 to 13.73 HKD [6] - Kuaishou-W (01024.HK) repurchased 755,000 shares for 49.9509 million HKD, with buyback prices between 65.4 and 66.6 HKD [7]

Group 1 - The company anticipates an unaudited consolidated net profit for the fiscal year ending September 30, 2025, due to a significant turnaround in its listed equity investments, moving from a loss of approximately 22.1 million HKD in the previous year to a profit of about 125 million HKD in the current year [1] - The expected net profit for the current fiscal year is projected to be between approximately 115 million HKD and 140 million HKD, compared to an unaudited net loss of about 19.9 million HKD in the previous year [1]

Core Viewpoint - The company anticipates a significant turnaround in financial performance, projecting a net profit for the fiscal year ending September 30, 2025, compared to a loss in the previous year [1] Financial Performance - The company expects to achieve an unaudited consolidated net profit ranging between approximately HKD 115 million and HKD 140 million for the current fiscal year [1] - This change is primarily attributed to the performance of the company's listed equity investments, which shifted from a loss of approximately HKD 22.1 million in the previous year to a profit of about HKD 125 million in the current year [1] - In the previous fiscal year, the company reported an unaudited net loss of approximately HKD 19.9 million [1]

正面盈利預告 本公佈乃本公司根據證券及期貨條例第XIVA 部項下之內幕消息條文及上市規 則第13.09(2)(a)條而刊發。 董事會謹此通知股東及潛在投資者，根據本集團截至二零二五年九月三十日止 年度之未經審核管理賬目及董事會目前可獲得的資料而作出的初步評估，比對 截至二零二四年九月三十日止年度所錄得的經審核綜合淨虧損，預期本集團於 截至二零二五年九月三十日止年度錄得未經審核綜合淨溢利。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Capital VC Limited 首都創投有限公司 （於開曼群島註冊成立之有限公司 並以CNI VC Limited名稱在香港經營業務） （股份代號：02324） 陳昌義 本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 本公佈乃首都創投有限公司（「本公司」，及連同其附屬公司統稱「本集團」）根據 香港法例第571章證券及期貨條例（「證券及期貨條例」）第XIVA部項下之內幕消息 條文（定義見香港聯合交易所有限公司 ...

Group 1 - The company, Capital Venture (02324.HK), announced a board meeting scheduled for December 30, 2025, to consider and approve the audited final results for the year ending September 30, 2025, and to discuss the proposal for dividend distribution, if any [1] - The meeting will also address other matters related to the company's operations and financial performance [1]